Trevi Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

TRVI$14.91-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Trevi Ther apeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Amounts in thousands, except share amounts)

Additional · Accumulated Other · Total
Common Stock · Paid- · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	in Capital	(Loss) Income	Deficit	Equity
Balance at June 30, 2026	142,420,883	$142	$682,582	$(425)	$(360,793)	$321,506
Stock-based compensation	—	—	3,366	—	—	3,366
Issuance of common stock from exercise of stock options	108,391	1	410	—	—	411
Unrealized losses on available-for-sale marketable securities	—	—	—	(1,075)	—	(1,075)
Net loss	—	—	—	—	(21,452)	(21,452)
Balance at September 30, 2026	142,529,274	$143	$686,358	$(1,500)	$(382,245)	$302,756
Balance at June 30, 2025	121,775,753	$122	$508,033	$24	$(309,686)	$198,493
Stock-based compensation	—	—	1,243	—	—	1,243
Issuance of common stock from exercise of stock options	477,485	—	1,123	—	—	1,123
Issuance of common stock from pre-funded warrant exercise	5,961,875	6	(6)	—	—	—
Unrealized gains on available-for-sale marketable securities	—	—	—	6	—	6
Proceeds from disgorgement of beneficial owner's short-swing profits	—	—	725	—	—	725
Net loss	—	—	—	—	(11,802)	(11,802)
Balance at September 30, 2025	128,215,113	$128	$511,118	$30	$(321,488)	$189,788

Additional · Accumulated Other · Total
Common Stock · Paid- · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	in Capital	(Loss) Income	Deficit	Equity
Balance at December 31, 2025	128,306,056	$128	$512,772	$148	$(329,804)	$183,244
Stock-based compensation	—	—	8,829	—	—	8,829
Issuance of common stock from exercise of stock options	876,664	2	2,352	—	—	2,354
Issuance of common stock from Employee Stock Purchase Plan	6,554	—	66	—	—	66
Issuance of common stock under offering, less issuance costs	13,340,000	13	162,339	—	—	162,352
Unrealized losses on available-for-sale marketable securities	—	—	—	(1,648)	—	(1,648)
Net loss	—	—	—	—	(52,441)	(52,441)
Balance at September 30, 2026	142,529,274	$143	$686,358	$(1,500)	$(382,245)	$302,756
Balance at December 31, 2024	93,602,631	$94	$386,534	$61	$(287,045)	$99,644
Stock-based compensation	—	—	3,835	—	—	3,835
Issuance of common stock from exercise of stock options	772,857	—	1,854	—	—	1,854
Issuance of common stock from Employee Stock Purchase Plan	15,898	—	59	—	—	59
Issuance of common stock from warrant exercise	7,851,852	8	10,749	—	—	10,757
Issuance of common stock from pre-funded warrant exercise	5,961,875	6	(6)	—	—	—
Issuance of common stock under offering, less issuance costs	20,010,000	20	107,368	—	—	107,388
Unrealized losses on available-for-sale marketable securities	—	—	—	(31)	—	(31)
Proceeds from disgorgement of beneficial owner's short-swing profits	—	—	725	—	—	725
Net loss	—	—	—	—	(34,443)	(34,443)
Balance at September 30, 2025	128,215,113	$128	$511,118	$30	$(321,488)	$189,788

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.